ArticleBiotechnology letters2026
Bioinformatic evaluation of ClpP as a vaccine target in Streptococcus pneumoniae.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo conduct a comprehensive bioinformatic analysis to assess the immunogenicity and conservation profiles of ClpP in Streptococcus pneumoniae, thereby verifying its feasibility as a candidate vaccine target.
methodsThe nucleotide and amino acid sequences of the clpP gene were obtained from the NCBI database. The fundamental characterizations of ClpP were retrieved from the public database PneumoWiki. NetPhos was used to predict phosphorylation sites, whereas SOPMA, Swiss-Model and STRING were employed to analyze secondary/tertiary structures and functional interaction network, respectively. Antigenic epitope mapping was carried out using DNASTAR, SYFPEITHI, NetMHCIIpan 4.0 and NetMHC. Multiple sequence alignment (MSA) was performed using Jalview software to analyze the conservation of the predicted epitopes across S. pneumoniae strains. Concurrently, a phylogenetic tree was constructed to evaluate the cross-species conservation of the ClpP protein.
resultsClpP (196 aa, pI 4.74) showed high hydrophobicity and without signal peptides/transmembrane domains. Phosphorylation sites (Ser/Thr/Tyr) were identified. The secondary structure of ClpP consists of 94 α-helices, 37 β-strands and 65 random coils. The functional interaction network of ClpP involves 10 interacting partners. Immunoinformatic analysis further detected immunodominant B-cell and T-cell epitopes within the ClpP sequence.
conclusionTaken together, these data suggest that ClpP exhibits robust immunogenicity and multiple antigenic epitopes, supporting its potential as a peptide-based vaccine candidate against S. pneumoniae.
Indexed as
Identifiers
41670831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.